Trial Profile

An Open, Single Arm, Multicenter, Exploratory Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type Patients With Metastatic Colorectal Carcinoma as 1st Therapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary) ; Capecitabine; Oxaliplatin
Indications Carcinoma; Colon cancer; Colorectal cancer; Liver metastases; Rectal cancer
Focus Therapeutic Use
Acronyms ALTER-C-002

20 Jan 2024 Updated overall survival results (at the data cutoff of May 29, 2023) presented at the 2024 Gastrointestinal Cancers Symposium.
06 Jun 2023 Results investigating the value of ctDNA in predicting treatment response and PFS in mCRC patients treated with anlotinib plus CAPEOX as first-line therapy, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
21 Jan 2023 Updated results (at the data cutoff :19 August 2022) presented at the 2023 Gastrointestinal Cancers Symposium.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com